Abstract:BackgroundHepatocellular carcinoma (HCC) is one of the leading causes of cancer-associated deaths worldwide. Although recent studies have proposed different biomarkers for HCC progression and therapy resistance, a better understanding of the molecular mechanisms underlying HCC progression and recurrence, as well as the identification of molecular markers with a higher diagnostic accuracy, are necessary for the development of more effective clinical management strategies. Here, we aimed to identify novel players in HCC progression.MethodsSPRYD4 mRNA and protein expression analyses were carried out on a normal liver-derived cell line (HL-7702) and four HCC-derived cell lines (HepG2, SMMC7721, Huh-7, BEL-7402) using qRT-PCR and Western blotting, respectively. Cell proliferation Cell Counting Kit-8 (CCK-8) assays, protein expression analyses for apoptosis markers using Western blotting, and Caspase-Glo 3/7 apoptosis assays were carried out onthe four HCC-derived cell lines. Expression comparison, functional annotation, gene set enrichment, correlation and survival analyses were carried out on patient data retrieved fromthe NCBI Gene module,the NCBI GEO database andthe TCGA database.ResultsThrough a meta-analysis we found that the expression of SPRYD4was downregulated in primary HCC tissues compared to non-tumor tissues. We also found that the expression of SPRYD4 was downregulated in HCC-derived cells compared to normal liver-derived cells. Subsequently, we found that the expression of SPRYD4 was inversely correlated with a gene signature associated with HCC cell proliferation. Exogenous SPRYD4 expression was found to inhibit HCC cell proliferation by inducing apoptotic cell death. We also found that SPRYD4 expressionwas associated with a good prognosis and that its expression became downregulated when HCCs progressed towards more aggressive stages and higher grades. Finally, we found that SPRYD4 expression may serve as a biomarker for a good overall and relapse-free survival in HCC patients.ConclusionsOur data indicate that a decreased SPRYD4 expression may serve as an independent predictor for a poor prognosis in patients with HCC and that increased SPRYD4 expression may reduce HCC growth and progression through the induction of apoptotic cell death, thereby providing a potential therapeutic target.

Role of SPRY4 in health and disease

Lower Expression of SPRY4 Predicts a Poor Prognosis and Regulates Cell Proliferation in Colorectal Cancer.

The Role of Sprouty1 in the Proliferation, Differentiation and Apoptosis of Epidermal Keratinocytes

SPRY4-IT1: A Novel Oncogenic Long Non-Coding RNA in Human Cancers

Novel Tumor Suppressor SPRYD4 Inhibits Tumor Progression in Hepatocellular Carcinoma by Inducing Apoptotic Cell Death

Sprouty4 Mediates Amphiregulin-Induced Down-Regulation of E-cadherin and Cell Invasion in Human Ovarian Cancer Cells.

Sprouty4 Correlates with Favorable Prognosis in Perihilar Cholangiocarcinoma by Blocking the FGFR-ERK Signaling Pathway and Arresting the Cell Cycle.

Sprouty3 and Sprouty4, Two Members of a Family Known to Inhibit FGF-Mediated Signaling, Exert Opposing Roles on Proliferation and Migration of Glioblastoma-Derived Cells

Suppression of Spry4 Enhances Cancer Stem Cell Properties of Human MDA-MB-231 Breast Carcinoma Cells.

Loss of SPRY2 contributes to cancer-associated fibroblasts activation and promotes breast cancer development

SPRY4-AS1, A Novel Enhancer RNA, is a Potential Novel Prognostic Biomarker and Therapeutic Target for Hepatocellular Carcinoma

SPROUTY2, a Negative Feedback Regulator of Receptor Tyrosine Kinase Signaling, Associated with Neurodevelopmental Disorders: Current Knowledge and Future Perspectives

Long Noncoding RNA SPRY4‐IT1 Promotes Proliferation and Metastasis of Hepatocellular Carcinoma Via Mediating TNF Signaling Pathway

Regulation of Cellular Levels of Sprouty2 Protein by Prolyl Hydroxylase Domain and Von Hippel-Lindau Proteins.

The Long Noncoding RNA SPRY4-IT1 Increases the Proliferation of Human Breast Cancer Cells by Upregulating ZNF703 Expression

EZH2-mediated Epigenetic Suppression of Long Noncoding RNA SPRY4-IT1 Promote S NSCLC Cell Proliferation and Metastasis by Affecting the Epithelial–mesenchymal Transition

Sprouty2 is associated with prognosis and suppresses cell proliferation and invasion in renal cell carcinoma.

Sprouty4 is epigenetically upregulated in human colorectal cancer

Increased SPRY1 expression activates NF-κB signaling and promotes pancreatic cancer progression by recruiting neutrophils and macrophages through CXCL12-CXCR4 axis

A Novel Sprouty4-ERK1/2-Wnt/β-catenin Regulatory Loop in Marrow Stromal Progenitor Cells Controls Osteogenic and Adipogenic Differentiation.

The Regulation of SPRY4 Intronic Transcript 1 (SPRY4-IT1) on KIT Signaling and Imatinib Resistance of Gastrointestinal Stromal Tumor (GIST) Cells